February 28, 2017 / 4:12 PM / 7 months ago

BUZZ-Valeant Pharmaceuticals: Set for worst day since November

(Updates)

** Canadian drugmaker’s U.S.-listed shares slide 8.62 pct to $15.27; set for worst day since November

** Says 2017 would be another year of transition with revenue falling as much as 8 percent amid drug pricing pressure and fewer prescriptions

** It still does not appear that management has a realistic outlook on its organic growth - Mizuho Securities USA analyst Irina Koffler

** Q4 report likely to add pressure on VRX as CEO Joseph Papa tries to rebuild business and regain investor confidence following scrutiny of company’s pricing and accounting practices

** Graphic on VRX valuation (bit.ly/2lgCQE8)

** Shares of specialty drugmaker Mallinckrodt down 4 pct; Mylan down 2 pct

** Including the 8.62 percent gain in the session at 11:04 am ET, shares of Valeant were up 5.1 percent YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below